UPDATED: Hedge fund aims to oust Depomed board for ‘troubling record’

Eric Palmer If Depomed thought it was free to chart its own course after foiling a takeover by Horizon Pharma last year, it can think again. A hedge fund practiced in the art of board ...

Depomed isn’t anti-takeover, CEO says. It was just anti-Horizon

Carly Helfand SAN FRANCISCO–Let Depomed be clear: it may not have been too keen on Horizon Pharma's buyout offer from last year, but that doesn't mean it's opposed ...

Stepped-up Nucynta sales push starts paying off for Depomed

Tracy Staton Depomed's relaunch of the Nucynta franchise–purchased earlier this year from Johnson & Johnson–is off to a running start, the company said last week ...

Horizon steps up its official Depomed pursuit with campaign website

Carly Helfand Horizon Pharma has officially begun mailing solicitation materials to shareholders of unwilling M&A target Depomed, including a letter related to its efforts to call ...

Depomed Launches Lazanda

barbara.lempert Signature SupportTM Program offers a full-range of services to simplify coverage support and patient assistance for patients taking Lazanda NEWARK, Calif., Oct. 28, ...

Depomed Acquires Archimedes’ Lazanda for $4M

barbara.lempert Depomed Announces Acquisition Of Lazanda® (fentanyl) Nasal Spray From Archimedes Pharma Limited NEWARK, Calif., July 29, 2013 /PRNewswire/ — Depomed, ...

Depomed Announces Appointment of Louis J. Lavigne, Jr. to Board of Directors

barbara.lempert NEWARK, Calif., July 8, 2013 /PRNewswire/ — Depomed, Inc. (NASDAQ: DEPO) today announced the appointment of Louis J. Lavigne, Jr. to the company’s Board ...

Depomed Receives Notice of Paragraph IV Certification Against Patents for Zipsor

barbara.lempert Depomed Receives Notice of Paragraph IV Certification Against Patents for Zipsor® MENLO PARK, Calif., July 2, 2013 /PRNewswire/ — Depomed, Inc. (Nasdaq:DEPO) ...
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS